PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15043806-8 2004 The available evidence best supports valproate as the first-line choice in the treatment of JME, although lamotrigine and topiramate may be appropriate choices in this setting. Valproic Acid 37-46 myoclonic epilepsy, juvenile, 2 Homo sapiens 92-95 12925366-6 2003 METHODS: We compared the efficacy of valproic acid, lamotrigine, and topiramate monotherapy or polytherapy in the control of different seizure types of JME, and compared their efficacy and tolerability with the efficacy and tolerability of phenytoin and carbamazepine. Valproic Acid 37-50 myoclonic epilepsy, juvenile, 2 Homo sapiens 152-155 12925366-10 2003 CONCLUSIONS: Lamotrigine and topiramate are effective alternative options to valproic acid in the treatment of JME. Valproic Acid 77-90 myoclonic epilepsy, juvenile, 2 Homo sapiens 111-114 12237068-13 2002 There was a subset of JME patients who had complete seizure control on other AEDs besides valproate. Valproic Acid 90-99 myoclonic epilepsy, juvenile, 2 Homo sapiens 22-25 8777552-1 1996 Currently valproic acid is considered to be the drug of first choice for juvenile myoclonic epilepsy (JME) resulting in a 70-90% control rate for all seizure types associated with JME. Valproic Acid 10-23 myoclonic epilepsy, juvenile, 2 Homo sapiens 102-105 11700996-1 2001 Sodium valproate (VPA) is considered the first choice drug in juvenile myoclonic epilepsy (JME). Valproic Acid 0-16 myoclonic epilepsy, juvenile, 2 Homo sapiens 91-94 11700996-1 2001 Sodium valproate (VPA) is considered the first choice drug in juvenile myoclonic epilepsy (JME). Valproic Acid 18-21 myoclonic epilepsy, juvenile, 2 Homo sapiens 91-94 9472131-5 1997 These results may suggest that slightly higher cortical excitability in untreated JME was controlled by valproate. Valproic Acid 104-113 myoclonic epilepsy, juvenile, 2 Homo sapiens 82-85 9863404-24 1998 In 24 patients with delayed diagnosis of JME the replacement of earlier medication with valproic acid (VPA) induced remission in 18 patients (75%) while 1 patient (4%) experienced a reduction in the number of seizures. Valproic Acid 88-101 myoclonic epilepsy, juvenile, 2 Homo sapiens 41-44 9863404-24 1998 In 24 patients with delayed diagnosis of JME the replacement of earlier medication with valproic acid (VPA) induced remission in 18 patients (75%) while 1 patient (4%) experienced a reduction in the number of seizures. Valproic Acid 103-106 myoclonic epilepsy, juvenile, 2 Homo sapiens 41-44 8777552-1 1996 Currently valproic acid is considered to be the drug of first choice for juvenile myoclonic epilepsy (JME) resulting in a 70-90% control rate for all seizure types associated with JME. Valproic Acid 10-23 myoclonic epilepsy, juvenile, 2 Homo sapiens 180-183 31440723-15 2019 Significance: In people with JME, valproate is an effective AED; levetiracetam emerged as an alternative. Valproic Acid 34-43 myoclonic epilepsy, juvenile, 2 Homo sapiens 29-32 2506006-5 1989 Valproate controls seizures in approximately 80% of JME patients and is recommended for successful management of this disorder. Valproic Acid 0-9 myoclonic epilepsy, juvenile, 2 Homo sapiens 52-55 3936330-8 1985 JME can be controlled very well by valproate and/or primidone. Valproic Acid 35-44 myoclonic epilepsy, juvenile, 2 Homo sapiens 0-3 29308656-11 2018 We also found that peri-IED synchronization in patients with JME was higher in drug-naive patients compared with those on sodium valproate monotherapy in theta, alpha, and beta bands. Valproic Acid 122-138 myoclonic epilepsy, juvenile, 2 Homo sapiens 61-64 30747367-3 2019 Approximately 85% of cases are well controlled with valproate, which remains the reference AED in JME but is nowadays considered unsafe for the expecting mother and her fetus. Valproic Acid 52-61 myoclonic epilepsy, juvenile, 2 Homo sapiens 98-101 30747367-21 2019 In patients with JME, valproate remains an essential and life-changing agent. Valproic Acid 22-31 myoclonic epilepsy, juvenile, 2 Homo sapiens 17-20 18684236-3 2008 Valproate is the drug of the first choice in men with JME. Valproic Acid 0-9 myoclonic epilepsy, juvenile, 2 Homo sapiens 54-57 27300146-2 2016 Valproate has proven to be the first-choice drug in JME for controlling the most common seizure types: myoclonic, absence, and generalized tonic-clonic (GTC). Valproic Acid 0-9 myoclonic epilepsy, juvenile, 2 Homo sapiens 52-55 27300146-3 2016 In this retrospective study, we analyzed seizure outcome in patients with JME using valproate monotherapy for a minimum period of one year. Valproic Acid 84-93 myoclonic epilepsy, juvenile, 2 Homo sapiens 74-77 27300146-11 2016 In patients with JME, it seems appropriate to use low doses of valproate (500mg to 1000mg) for initial treatment and then to determine if freedom from seizures was attained. Valproic Acid 63-72 myoclonic epilepsy, juvenile, 2 Homo sapiens 17-20 27082040-3 2016 The recent diktat from the European regulatory agency - recommending that sodium valproate should not be prescribed to female children, adolescents or women of childbearing potential unless other treatments were ineffective or not tolerated - has substantially changed the way JME is being managed in this population. Valproic Acid 74-90 myoclonic epilepsy, juvenile, 2 Homo sapiens 277-280 23673144-1 2013 Juvenile myoclonic epilepsy (JME) is managed with valproate in most patients; however, valproate is an antiepileptic drug that has relatively severe adverse effects, especially in women. Valproic Acid 50-59 myoclonic epilepsy, juvenile, 2 Homo sapiens 29-32 23673144-1 2013 Juvenile myoclonic epilepsy (JME) is managed with valproate in most patients; however, valproate is an antiepileptic drug that has relatively severe adverse effects, especially in women. Valproic Acid 87-96 myoclonic epilepsy, juvenile, 2 Homo sapiens 29-32 23673144-2 2013 We performed a prospective, open-label, randomized observational study for comparison of efficacy and tolerability between topiramate and valproate in patients with JME. Valproic Acid 138-147 myoclonic epilepsy, juvenile, 2 Homo sapiens 165-168 23673144-13 2013 Our findings suggest that valproate may be replaced with topiramate, especially for the patients with JME who do not tolerate valproate. Valproic Acid 26-35 myoclonic epilepsy, juvenile, 2 Homo sapiens 102-105 23103316-14 2012 In conclusion, there was poor sleep quality in patients with JME compared to controls, especially those on valproate who had altered sleep architecture. Valproic Acid 107-116 myoclonic epilepsy, juvenile, 2 Homo sapiens 61-64 21494841-3 2011 The drug of first choice in the treatment of JME is sodium valproate, which has a response rate of up to 80%. Valproic Acid 52-68 myoclonic epilepsy, juvenile, 2 Homo sapiens 45-48 24296772-14 2013 The patient was later started on tablet divalproex sodium, which the patient continues to take on a long-term basis, especially because of its efficacy as an antimigraine prophylaxis agent and a potent drug against JME. Valproic Acid 40-57 myoclonic epilepsy, juvenile, 2 Homo sapiens 215-218 23774821-1 2013 Juvenile myoclonic epilepsy (JME) is a frequent idiopathic generalised epilepsy syndrome with typical clinical and EEG features that can usually be controlled by valproate monotherapy. Valproic Acid 162-171 myoclonic epilepsy, juvenile, 2 Homo sapiens 29-32 22120338-2 2012 However, almost 30% of patients with juvenile myoclonic epilepsy (JME) are valproate-resistant. Valproic Acid 75-84 myoclonic epilepsy, juvenile, 2 Homo sapiens 66-69 21093381-5 2011 Antiepileptic drug usage was comparable for both sexes except that fewer women with JME were prescribed valproate. Valproic Acid 104-113 myoclonic epilepsy, juvenile, 2 Homo sapiens 84-87 16814521-1 2006 PURPOSE: Patients with juvenile myoclonic epilepsy (JME) may be resistant or show adverse effects to valproate. Valproic Acid 101-110 myoclonic epilepsy, juvenile, 2 Homo sapiens 52-55 19300607-3 2007 Valproate is unquestionably the drug of the first choice in men with JME. Valproic Acid 0-9 myoclonic epilepsy, juvenile, 2 Homo sapiens 69-72 17037947-6 2006 Valproic acid is the primary antiepileptic drug (AED) used for JME, but some newer AEDs may be effective alternatives. Valproic Acid 0-13 myoclonic epilepsy, juvenile, 2 Homo sapiens 63-66 15634623-1 2004 The recommended treatment for juvenile myoclonic epilepsy (JME) is valproate (VPA). Valproic Acid 67-76 myoclonic epilepsy, juvenile, 2 Homo sapiens 59-62 15634623-1 2004 The recommended treatment for juvenile myoclonic epilepsy (JME) is valproate (VPA). Valproic Acid 78-81 myoclonic epilepsy, juvenile, 2 Homo sapiens 59-62